There is now compelling evidence to further evaluate lower doses of abiraterone acetate in men with metastatic prostate cancer: It should be safer, may be as effective and less expensive

Pedro Isaacsson Velho, Mario A. Eisenberger

Research output: Contribution to journal › Letter › peer-review

3 Scopus citations

Fingerprint

Dive into the research topics of 'There is now compelling evidence to further evaluate lower doses of abiraterone acetate in men with metastatic prostate cancer: It should be safer, may be as effective and less expensive'. Together they form a unique fingerprint.